Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.46 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5829422 | 0.96 | L3MBTL1 (0.47) | L3MBTL1ATMIDO1TAAR1MEN1 | |
| Bromide SCHEMBL1149819 | 0.86 | ABCB1 (0.48) | L3MBTL1ATMMEN1KMT2AALDH1A1 | |
| Bromide SCHEMBL5828497 | 0.85 | TRAP1 (0.39) | L3MBTL1ATMIDO1TAAR1MEN1 | |
| Bromide SCHEMBL4169546 | 0.82 | SLC6A2 (0.45) | ALDH1A1SLC6A2SLC6A4KCNH2 | |
| Bromide SCHEMBL4183772 | 0.82 | L3MBTL1 (0.50) | L3MBTL1ATMMEN1KMT2AALDH1A1 | |
| Bromide SCHEMBL7804211 | 0.82 | HTR2A (0.54) | IDO1TAAR1MEN1KMT2ACA12 | |
| Bromide SCHEMBL5829383 | 0.82 | L3MBTL1 (0.42) | L3MBTL1ATMALDH1A1MAPT | |
| Bromide SCHEMBL4180528 | 0.81 | CA1 (0.43) | L3MBTL1ATMALDH1A1TRAP1CA12 | |
| Bromide SCHEMBL17337941 | 0.80 | SLC6A2 (0.42) | L3MBTL1IDO1HTTALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL8703957 | 0.80 | ABCB1 (0.36) | L3MBTL1ATMMAPTTRAP1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114249718-A | Sulfonium salt derivative and preparation method and medical application thereof | 中国药科大学 | 2022-03-29 | — | — | CN | claimed |
| CN-114249718-B | Sulfonium salt derivative, preparation method and medical application thereof | 中国药科大学 | 2023-09-22 | — | — | CN | disclosed |
| EP-4028402-A1 | RADIOLABELED COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-07-20 | — | — | EP | disclosed |
| US-20220202963-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-06-30 | — | — | US | disclosed |
| CN-114650994-A | Radiolabelled compounds | 豪夫迈·罗氏有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-114249718-A | Sulfonium salt derivative and preparation method and medical application thereof | 中国药科大学 | 2022-03-29 | — | — | CN | disclosed |
| WO-2021048241-A1 | RADIOLABELED COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-18 | — | — | WO | disclosed |
| US-10201545-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-9421210-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160193160-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-7230031-B2 | Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-7094798-B1 | Inhibitors of checkpoint kinases (Wee1 and Chk1) | PFIZER INC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20050250836-A1 | Inhibitors of checkpoint kinases (Wee1 and Chk1) | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| EP-1216223-B1 | NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES | BAYER HEALTHCARE AG (DE) | 2005-11-09 | — | — | EP | disclosed |
| US-20050085541-A1 | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1501831-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1471049-A1 | NOVEL THYROID HORMONE RECEPTOR LIGAND, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003091255-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-1216223-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES | Bayer Aktiengesellschaft (DE) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019778-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085541-A1 | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | TSHR, THRA, THRB | CHRM2 70/4885CHRM1 72/4885L3MBTL1 1647/4885 |
| US-20050250836-A1 | Inhibitors of checkpoint kinases (Wee1 and Chk1) | WEE1, WEE2, CHEK1 | CHRM2 4834/4885CHRM1 4639/4885L3MBTL1 1072/4885 |
| US-20220202963-A1 | RADIOLABELED COMPOUNDS | MGLL, PNLIP, LPL | CHRM2 3791/4885CHRM1 3298/4885L3MBTL1 369/4885 |
| US-20160193160-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | CHRM2 4524/4885CHRM1 4469/4885L3MBTL1 1912/4885 |
| US-10201545-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ALDH1A2, STARD3, TXNRD2 | CHRM2 4524/4885CHRM1 4469/4885L3MBTL1 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.